New Releases from NCBI BookshelfErdafitinib (Balversa): Indication: For the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy: Reimbursement Recommendation [Internet].Erdafitinib (Balversa): Indication: For the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Balversa should be reimbursed by public drug plans for the treatment of locally advanced […]